Bayer AG (XTER:BAYN) Cyclically Adjusted Revenue per Share: €52.92 (As of Mar. 2026)


XTER:BAYN Bayer AG XTER:BAYN
56 GF Score
Price €49.64
GF Value €27.39
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Cyclically Adjusted Revenue per Share?

Bayer AG XTER:BAYN -2.32% 56 Cyclically Adjusted Revenue per Share is €52.92 as of Mar. 2026. GuruFocus rates XTER:BAYN with a GF Score™ of 56/100 and a GF Value™ of €27.39 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bayer AG's adjusted revenue per share for the three months ended in Mar. 2026 was €13.645. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €52.92 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bayer AG's average Cyclically Adjusted Revenue Growth Rate was -2.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bayer AG was 3.90% per year. The lowest was -0.60% per year. And the median was 2.10% per year.

As of today (2026-07-09), Bayer AG's current stock price is €49.64. Bayer AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €52.92. Bayer AG's Cyclically Adjusted PS Ratio of today is 0.94.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bayer AG was 2.52. The lowest was 0.35. And the median was 1.08.


Bayer AG  (XTER:BAYN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bayer AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=49.64/52.92
=0.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bayer AG was 2.52. The lowest was 0.35. And the median was 1.08.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bayer AG Cyclically Adjusted Revenue per Share Related Terms


Bayer AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bayer AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Cyclically Adjusted Revenue per Share Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.17 53.64 54.41 54.22 52.66

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.09 53.60 53.22 52.66 52.92

XTER:BAYN vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bayer AG's Cyclically Adjusted PS Ratio falls into.


XTER:BAYN
56GF Score
Bayer AG XTER:BAYN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bayer AG's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=13.645/131.2583*131.2583
=13.645

Current CPI (Mar. 2026) = 131.2583.

Bayer AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 14.309 100.717 18.648
201609 9.986 101.017 12.976
201612 10.390 101.217 13.474
201703 11.109 101.417 14.378
201706 9.844 102.117 12.653
201709 9.062 102.717 11.580
201712 9.707 102.617 12.416
201803 10.319 102.917 13.161
201806 10.354 104.017 13.066
201809 9.449 104.718 11.844
201812 10.560 104.217 13.300
201903 12.500 104.217 15.743
201906 10.912 105.718 13.548
201909 10.006 106.018 12.388
201912 10.942 105.818 13.573
202003 13.075 105.718 16.234
202006 10.234 106.618 12.599
202009 8.658 105.818 10.740
202012 10.174 105.518 12.656
202103 12.549 107.518 15.320
202106 11.048 108.486 13.367
202109 9.956 109.435 11.941
202112 11.317 110.384 13.457
202203 14.901 113.968 17.162
202206 13.048 115.760 14.795
202209 11.483 118.818 12.685
202212 12.215 119.345 13.434
202303 14.646 122.402 15.706
202306 11.242 123.140 11.983
202309 10.527 124.195 11.126
202312 12.074 123.773 12.804
202403 14.011 125.038 14.708
202406 11.343 125.882 11.827
202409 10.146 126.198 10.553
202412 11.939 127.041 12.335
202503 13.984 127.779 14.365
202506 10.931 128.412 11.173
202509 9.833 129.255 9.985
202512 11.643 129.361 11.814
202603 13.645 131.258 13.645

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €52.92 mean?
Bayer AG (XTER:BAYN) has a Cyclically Adjusted Revenue per Share of €52.92 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bayer AG and its competitors.
Is Bayer AG's Cyclically Adjusted Revenue per Share too high?
Bayer AG's current Cyclically Adjusted Revenue per Share is €52.92. Overall, Bayer AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Bayer AG's Cyclically Adjusted Revenue per Share of €52.92 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bayer AG and its competitors. Bayer AG's current Cyclically Adjusted Revenue per Share is €52.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XTER:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is €27.39, compared to a current price of €49.64 — trading 81.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €52.92. Bayer AG's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bayer AG (XTER:BAYN), the current Cyclically Adjusted Revenue per Share is €52.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XTER:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of €49.64 is trading 81.2% above its estimated GF Value™ of €27.39. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XTER:BAYN:

  • Cyclically Adjusted Revenue per Share: €52.92
  • GF Value™: €27.39 vs. price of €49.64 (81.2% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the XTER:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
56GF Score

Get the complete analysis for XTER:BAYN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€49.64
Price
€27.39
GF Value